Is psychedelic therapy scientifically proven to be effective?
Psychedelic therapy, which involves substances such as psilocybin, LSD, DMT, MDMA Early studies suggest that ketamine, when used in combination with psychotherapy, shows promising results in the treatment of certain mental health conditions, such as treatment-resistant depression and post-traumatic stress disorder (PTSD). These studies suggest that psychedelics may help to break entrenched patterns of thinking and reduce symptoms in patients for whom traditional treatments are not sufficiently effective.
Nevertheless, the scientific evidence is still limited. Many studies are small-scale, and there is still insufficient knowledge about the long-term effects and potential risks of psychedelic therapy. To reduce these gaps in knowledge, organisations such as ZonMw and the European Union are investing in larger-scale, standardised research into the safety and effectiveness of these treatments.
Several studies are currently being carried out in the Netherlands into the therapeutic uses of psychedelics. In the spring of 2025, the University Medical Centre Groningen (UMCG) will launch a study into the effects of psilocybin on patients with treatment-resistant depression. In addition, the UMCG coordinates a European consortium conducting research into the use of psilocybin to address psychological distress in patients with incurable, progressive diseases.
In summary, the initial research findings on psychedelic therapy are promising, but further large-scale and rigorous research is needed to definitively establish its effectiveness and safety.
